Jakson kuvaus
Episode 163 — 08 November 2026
HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value narrative; FTC-CVS insulin settlement exposes PBM practices; ICER early-phase advice aims to de-risk development.
Hosted by Marcus and Sara.
Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
Full transcript and sources at outcomes-analytica.no/podcast

